MDM2 and cancer: A subset of 58 cancer cell lines with the TP53 Arg248 Trp variant appeared insensitive to the MDM2 inhibitor AMGMDS3, while the EGFR Thr263 Pro mutant compared to the wild-type Ba/F3 cell line showed some sensitivity to the tyrosine kinase inhibitor (TKI) erlotinib [19,20].